As per our report, the size of the Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market in the Asia Pacific has been estimated at USD 1.99 billion in 2020 and predicted to reach USD 3.56 billion by 2025, witnessing a CAGR of 12.30% during the forecast period.
Attention deficit hyperactivity disorder (ADHD), is one of the most common neurological/psychiatric disorders among children and adolescents. ADHD is commonly observed in children (<12 years age) as compared to adolescents. ADHD is also described as a hyperkinetic disorder/ attention deficit disorder or neuropsychiatric disorder. The exact cause for ADHD is not clear but, expected to be resulted due to genetic factors and environmental influences. ADHD results in improper functioning of the nervous system that led to attention deficit and hyperactivity/impulsiveness conditions. ADHD is characterized by certain symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The symptoms of attention deficit hyperactivity disorder (ADHD) are controlled by different modalities such as medication (stimulants-amphetamines; non-stimulants-atomoxetine), psychotherapy (behavior therapy, cognitive behavioral therapy), and education/training (parent management training, family training).
The growing healthcare industry, increasing initiatives from the government to provide better treatment solutions for mental illness conditions, growing focus of foreign pharmaceutical companies on the Asian market, presence of a huge population, and rising number of mental disorders are driving the growth of attention deficit hyperactivity disorder therapeutics market in Asia-Pacific region.
However, high costs pertaining to the treatment and limited adoption of ADHD therapeutics are restraining the growth of the attention deficit hyperactivity disorder therapeutics market in the Asia-Pacific region.
This research report on the APAC ADHD Therapeutics Market is segmented and sub-segmented into the following categories:
By Medication:
By Psychotherapy:
By Education Or Training:
By Country:
Most promising companies in the APAC Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market profiled in this report are Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.) and Curemark, LLC. (U.S.).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Introduction
5.2 Treatment By Medication
5.2.1 Introduction
5.2.2 Stimulants
5.2.2.1 Introduction
5.2.2.2 Amphetamines
5.2.2.3 Methylphenidate
5.2.2.4 Dextroamphetamine
5.2.2.5 Dexmethylphenidate
5.2.3 Non-Stimulants
5.2.3.1 Introduction
5.2.3.2 Atomoxetine
5.2.3.3 Bupropion
5.2.3.4 Guanfacine
5.3 Treatment By Psychotherapy
5.3.1 Introduction
5.3.2 Behavior Therapy
5.3.3 Cognitive Behavioral Therapy
5.3.4 Interpersonal Psychotherapy
5.3.5 Family Therapy
5.4 Treatment By Education or Training
5.3.1 Introduction
5.3.2 Parent Management Training
5.3.3 Social Skills Training
5.3.4 School-Based Interventions
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 Soth Korea
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Shire plc (Ireland)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Neos Therapeutics, Inc. (U.S.)
8.3 Eli Lilly and Company (U.S.)
8.4 Pfizer Inc. (U.S.)
8.5 Alcobra Ltd. (Israel)
8.6 Supernus Pharmaceuticals, Inc. (U.S.)
8.7 Noven Pharmaceuticals, Inc. (U.S.)
8.8 Novartis AG (Switzerland)
8.9 Johnson & Johnson (U.S.)
8.10 Curemark, LLC., (U.S.)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
